

Anne C Moore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8931580/publications.pdf>

Version: 2024-02-01

55
papers

3,364
citations

126858

33
h-index

161767

54
g-index

61
all docs

61
docs citations

61
times ranked

4120
citing authors

#	ARTICLE	IF	CITATIONS
1	A Video-Based Behavioral Intervention Associated with Improved HPV Knowledge and Intention to Vaccinate. <i>Vaccines</i> , 2022, 10, 562.	2.1	5
2	Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 54-72.	2.0	38
3	The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia. <i>Journal of Neuroinflammation</i> , 2021, 18, 37.	3.1	12
4	Immune responses induced by inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in neonatal pigs using different adjuvants. <i>Veterinary Immunology and Immunopathology</i> , 2021, 232, 110170.	0.5	8
5	Early immune responses in skin and lymph node after skin delivery of Toll-like receptor agonists in neonatal and adult pigs. <i>Vaccine</i> , 2021, 39, 1857-1869.	1.7	4
6	Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection. <i>Vaccines</i> , 2021, 9, 299.	2.1	10
7	Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE ^{−/−} mice in the presence and absence of immunomodulation with fingolimod. <i>Data in Brief</i> , 2021, 36, 107146.	0.5	3
8	Parent Attitudes about Childhood Vaccines: Point Prevalence Survey of Vaccine Hesitancy in an Irish Population. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 188.	0.6	13
9	A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119390.	2.6	29
10	Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 331-337.	1.5	32
11	The immune system and stroke: from current targets to future therapy. <i>Immunology and Cell Biology</i> , 2019, 97, 5-16.	1.0	78
12	Immunomodulatory Therapeutic Strategies in Stroke. <i>Frontiers in Pharmacology</i> , 2019, 10, 630.	1.6	45
13	Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs. <i>Journal of Controlled Release</i> , 2019, 308, 14-28.	4.8	29
14	Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of M2 markers. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1455-1465.	2.0	2
15	Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies. <i>Journal of Controlled Release</i> , 2019, 311-312, 96-103.	4.8	35
16	A systematic approach to map the adolescent human papillomavirus vaccine decision and identify intervention strategies to address vaccine hesitancy. <i>Public Health</i> , 2019, 177, 71-79.	1.4	11
17	Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine. <i>Veterinary Immunology and Immunopathology</i> , 2019, 212, 27-37.	0.5	19
18	Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats. <i>Vaccine</i> , 2018, 36, 4265-4277.	1.7	17

#	ARTICLE	IF	CITATIONS
19	Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents. <i>Vaccine</i> , 2017, 35, 4896-4904.	1.7	18
20	The success of microneedle-mediated vaccine delivery into skin. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2975-2983.	1.4	370
21	Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods. <i>Journal of Controlled Release</i> , 2016, 225, 192-204.	4.8	86
22	Dissolvable microneedle fabrication using piezoelectric dispensing technology. <i>International Journal of Pharmaceutics</i> , 2016, 500, 1-10.	2.6	55
23	Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use. <i>Vaccine</i> , 2016, 34, 723-734.	1.7	40
24	Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. <i>Vaccine</i> , 2015, 33, 3248-3255.	1.7	30
25	Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles. <i>International Journal of Pharmaceutics</i> , 2014, 472, 206-213.	2.6	36
26	Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 200-211.	2.0	111
27	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. <i>Scientific Reports</i> , 2014, 4, 6154.	1.6	46
28	Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 1451-1462.	1.2	39
29	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. <i>Scientific Reports</i> , 2013, 3, 1443.	1.6	67
30	The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013, 3, 1706.	1.6	36
31	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. <i>Journal of Controlled Release</i> , 2012, 159, 34-42.	4.8	141
32	Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 389-404.	2.4	84
33	Soluble IL-2R β (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice. <i>PLoS ONE</i> , 2012, 7, e47748.	1.1	55
34	Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. <i>PLoS ONE</i> , 2011, 6, e22442.	1.1	68
35	Determination of parameters for successful spray coating of silicon microneedle arrays. <i>International Journal of Pharmaceutics</i> , 2011, 415, 140-149.	2.6	114
36	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. <i>Cell Host and Microbe</i> , 2009, 5, 95-105.	5.1	65

#	ARTICLE	IF	CITATIONS
37	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . <i>European Journal of Immunology</i> , 2008, 38, 732-741.	1.6	95
38	Effective induction of high-titer antibodies by viral vector vaccines. <i>Nature Medicine</i> , 2008, 14, 819-821.	15.2	148
39	Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14017-14022.	3.3	236
40	Single-Dose Protection against <i>Plasmodium berghei</i> by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A. <i>Journal of Virology</i> , 2008, 82, 3822-3833.	1.5	67
41	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. <i>Infection and Immunity</i> , 2007, 75, 5819-5826.	1.0	43
42	Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. <i>Expert Review of Vaccines</i> , 2007, 6, 111-121.	2.0	18
43	Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage <i>P. falciparum</i> malaria in non-immune volunteers. <i>Vaccine</i> , 2006, 24, 3026-3034.	1.7	65
44	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length <i>Plasmodium falciparum</i> Circumsporozoite Protein. <i>Infection and Immunity</i> , 2006, 74, 2706-2716.	1.0	62
45	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. <i>Journal of Immunology</i> , 2005, 175, 7264-7273.	0.4	89
46	Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2005, 175, 599-606.	0.4	60
47	A <i>Plasmodium falciparum</i> candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 290-295.	3.3	59
48	Progress in DNA-based heterologous prime-boost immunization strategies for malaria. <i>Immunological Reviews</i> , 2004, 199, 126-143.	2.8	115
49	Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells. <i>Cellular Immunology</i> , 2004, 228, 15-19.	1.4	17
50	Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. <i>Vaccine</i> , 2004, 22, 4326-4331.	1.7	18
51	Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice. <i>Journal of Virology</i> , 2002, 76, 243-250.	1.5	115
52	The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. <i>Vaccine</i> , 1999, 17, 2517-2527.	1.7	105
53	Approaches To New Vaccines. <i>Critical Reviews in Biotechnology</i> , 1998, 18, 257-282.	5.1	23
54	Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. <i>Vaccine</i> , 1995, 13, 1741-1749.	1.7	149

#	ARTICLE	IF	CITATIONS
55	Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6